This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
All Wales Medicines Strategy Group (AWMSG). Tipranavir (Aptivus®) oral solution. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2110. 2010
Tipranavir (Aptivus®) oral solution, co-administered with low dose ritonavir, is recommended as an option for use within NHS Wales for combination antiretroviral treatment of HIV-1 infection in highly pre-treated children from 2 to 12 years of age with virus resistant to multiple protease inhibitors. Tipranavir (Aptivus®) should only be used as part of an active combination antiretroviral regimen in patients with no other therapeutic options.
Tipranavir (Aptivus®) oral solution is not suitable for shared care within NHS Wales for the above indication.
Subject indexing assigned by CRD
Anti-HIV Agents; HIV Infections; Pyridines; Pyroness
Country of organisation
An English language summary is available.
Address for correspondence
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Date abstract record published